Cudraflavone B exhibits anti-inflammatory and anticancer properties; it acts as a dual inhibitor of COX-1 and COX-2; it blocks the translocation of nuclear factor kappa B (NF-κB) from the cytoplasm to the nucleus in macrophages, thereby inhibiting the gene expression and secretion of tumor necrosis factor alpha (TNFα); it triggers the mitochondrial apoptotic pathway, activates NF-κB, MAPK p38, and ERK, and induces SIRT1 expression; it suppresses the growth of human oral squamous cell carcinoma cells.